z-logo
Premium
Clinical applications of next‐generation sequencing‐based gene panel in patients with muscular dystrophy: Korean experience
Author(s) -
Seong M.W.,
Cho A.,
Park H.W.,
Seo S.H.,
Lim B.C.,
Seol D.,
Cho S.I.,
Park S.S.,
Chae J.H.
Publication year - 2016
Publication title -
clinical genetics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.543
H-Index - 102
eISSN - 1399-0004
pISSN - 0009-9163
DOI - 10.1111/cge.12621
Subject(s) - dysferlin , muscular dystrophy , medicine , creatine kinase , gene , limb girdle muscular dystrophy , genetic diagnosis , genetics , bioinformatics , mutation , biology
Muscular dystrophy ( MD ) is a genetically and clinically heterogeneous group of disorders. Here, we performed targeted sequencing of 18 limb‐girdle MD ( LGMD )‐related genes in 35 patients who were highly suspected of having MD . We identified one or more pathogenic variants in 23 of 35 patients (65.7%), and a genetic diagnosis was performed in 20 patients (57.1%). LGMD2B was the most common LGMD type, followed by LGMD1B , LGMD2A , and LGMD2G . Among the three major LGMD types in this group, LGMD1B was correlated with the lowest creatine kinase ( CK ) levels and the earliest onset, whereas LGMD2B was correlated with the highest CK levels and the latest onset. Thus, next‐generation sequencing‐based gene panels can be a helpful tool for the diagnosis of MDs , particularly in young children and those displaying atypical symptoms.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom